Nefiracetam

Drug Profile

Nefiracetam

Alternative Names: BRN 6848330; CCRIS 6729; DM 9384; DMPPA; DN-9384; DZL-221; HL-0812; HPI-001; Motiva; Translon

Latest Information Update: 02 Jun 2015

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Neuren Pharmaceuticals
  • Class Acetamides; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Calcium channel agonists; GABA receptor agonists; Nicotinic receptor agonists; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy
  • Discontinued Dementia; Major depressive disorder

Most Recent Events

  • 15 Mar 2011 Phase-II development is ongoing in US, Australia and Canada for Depression in post-stroke patients
  • 08 Jun 2010 Clinical development is ongoing
  • 12 Mar 2008 Phase-II clinical trials in Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top